New technology could lead to safer gene therapy

EU-funded scientists have developed a new, non-viral way of getting genes into a cell. The technique appears to avoid the side-effects, such as cancer, which can occur when viruses are used to smuggle genes into a cell. The scientists hope their discovery will 'simplify the way gene therapy is conducted, improve its overall safety and reduce the costs'.

The findings, published in the journal Nature Genetics, were supported by the EU-funded JUMPY (Transposon-based strategies for functional genomic analyses in Xenopus tropicalis, a vertebrate model system for developmental and biomedical research), INTHER ('Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies) and PERSIST (Persisting transgenesis) projects.

Gene therapy entails the insertion of genes into a patient's cells; it has proved effective in the treatment of a number of diseases which would otherwise be untreatable. It can be used for hereditary diseases (where a healthy gene is used to replace the faulty gene the patient has inherited), as well as for diseases affecting the heart and brain.

A good gene therapy technique has three characteristics: the therapeutic genes must be delivered to the right cells; the genes must remain active in the patient for a long time; and any undesired side effects should be minimised.

At the moment, viruses are often used as a vector to carry the genes into the target cell. However, this approach is associated with a number of side effects, including inflammation and even the development of cancer. Furthermore, the development of the viral vectors for use in clinical trials is often hampered by technical and regulatory hurdles.

In this latest study, the scientists turned to a natural gene smuggler - the transposons. Transposons are naturally occurring sections of DNA that have the ability to cut and paste themselves into foreign DNA.

The researchers constructed a highly active transposon that is able to carry the therapeutic gene into the target cell and integrate it into the host's DNA.

"We show for the first time that it is now possible to efficiently deliver genes into stem cells, particularly those of the immune system, using non-viral gene delivery," commented Marinee Chuah of the Flanders Institute for Biotechnology (VIB) in Belgium.

"Many groups have tried this for many years but without success. We are glad that we could now overcome this hurdle," added her colleague, Thierry Vandendriessche.

The researchers are now refining and testing their new-found technology for use against specific diseases, including cancer and genetic disorders.

The JUMPY project received EUR 1,183,220 from the 'Quality of life and management of living resources' budget line of the Fifth Framework Programme (FP5), the INTHER project received EUR 2,800,000 from the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6), and the PERSIST project has been allocated EUR 11,181,411 under the Health Theme of the Seventh Framework Programme (FP7).

For more information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...